期刊文献+

吗替麦考酚酸酯及其活性代谢物麦考酚酸的跨膜转运机制研究

Investigation on the Mechanism of Transmembrane Transport of Mycophenolate Mofetil and Its Active Metabolite Mycophenolic Acid
原文传递
导出
摘要 目的研究吗替麦考酚酸酯(mycophenolate mofetil,MMF)及其活性代谢物麦考酚酸(mycophenolic acid,MPA)的跨膜转运机制。方法建立Caco-2细胞单层模型,进行吗替麦考酚酸酯及麦考酚酸转运实验,用LC-MS/MS方法测定转运实验样品中吗替麦考酚酸酯和麦考酚酸浓度,计算表观通透系数Papp和外排率Pratio,评价药物转运及外排作用,P-糖蛋白(P-glycoprotein,P-gp)抑制剂维拉帕米用于评价P-gp在吗替麦考酚酸酯和麦考酚酸肠道吸收转运中的作用。结果麦考酚酸在10、50和100μmol·L-1的双向转运的表观通透系数Papp,ab[和Papp,ba]分别为(9.70±0.40)×106cm·s-1[(13.52±0.28)×106cm·s-1]、(9.35±0.62)×106cm·s-1[(11.38±0.59)×106cm·s-1]和(8.69±0.69)×106cm·s-1[(10.53±0.64)×106cm·s-1];外排率Pratio分别为1.39、1.22和1.22,维拉帕米明显降低了外排率。吗替麦考酚酸酯在穿过Caco-2细胞单层转运过程中大部分被水解为麦考酚酸,麦考酚酸转运的量随转运时间延长而不断增加,而吗替麦考酚酸酯转运的量随时间无明显变化。维拉帕米对吗替麦考酚酸酯转运无明显影响。结论麦考酚酸的跨膜转运受到由转运载体介导的主动转运外排作用影响,P-gp参与了麦考酚酸的跨膜转运。吗替麦考酚酸酯的跨膜转运不存在P-gp的作用,为被动转运。 OBJECTIVE To investigate the mechanism of transmembrane transport nf mycopheno|ate mofetil ( MMF) and its active metabolite mycophenolic acid ( MPA ). METHODS Caco-2 cell monolayer model was developed for MMF a,d MPA transporl experiment, and the LC-MS/MS method was used for the determination of MMF and MPA concentration in transport me- dium. The apparent permeability coefficient (Papp) and effiux ratio (Pratio) were calculated and used for the evaluation of the a- bility of drug transport arid drug effiux across Caco-2 eell monolayer. RESULTS The Papp of MPA in two-way transport experi- ment (Papp,ab andPapp.ba) at 10, 50 and 100 μmol·L^-1 were(9.70±0.40) ×10^6cm·s^-1[(13.52 ±0.28) ×10^6cm·s^-1,(9.35 ±0.62) ×10^6cm·s^-1[(11.38±0.59) ×10^6cm·s^-1],(8.69±0.69) ×10^6cm·s^-1[(10.53±0.64) ×10^6cm·s^-1) , respeetively. Pratio were 1. 39, 1.22 and 1.22, respectively. Pratoi of MPA was reduced by verapamil, a well- known P-glycoprotein inhibitor. MMF was mostly hydrolyzed to MPA during the transport process across the Caco-2 cell monnlay- er. The amount of MPA transported increased with time, but the amount of MMF transported changed not significantly over time and no significant eff)ct of verapamil was observed. CONCLUSION The transmembrane transport of MPA is affcted by active transport efflux mediated by transporter with P-gp involved. No effect of P-gp is found in MMF transmembrane lransport, which is passive transport.
出处 《中国药学杂志》 CAS CSCD 北大核心 2014年第4期322-328,共7页 Chinese Pharmaceutical Journal
关键词 吗替麦考酚酸酯 麦考酚酸 跨膜转运 机制 P-糖蛋白 mycopherlolate motetil mycophenolic acid transmembrane transport mechanism : P-glycoprotein
  • 相关文献

参考文献19

  • 1ALLISON A G, EUGUI E M. Mechanisms of action of mycophe- nolate mofetil in preventing acute and chronic allograft rejection [ J ]. Transplantation,2005,80 ( suppt 2) . 181-190.
  • 2STAATZ C E, TETT S E. Clinical pharmacokinetics and phar- macodynamics of mycophenolate in solid organ transplant recipi- ents[J]. Clin Pharmacokinet, 2007, 46(1 ) .13-58.
  • 3PAWINSKI T, DURLIK M, SZLASKA I, et al. Comparison of mycophenolic acid pharmacokineticparameters in kidney trans- plant patients within thefirst 3 months post-transplant[J]. J Clin Pharm Ther, 2006, 31 (1). 27-34. 83.
  • 4VAN HEST R M, MATHOT R A, VULTO A G, et al. Within- patient variability of mycophenolic acid exposure. Therapeutic drug monitoring from a clinical point of view [ J ]. Ther Drug Moult, 2006, 28(1).31-34.
  • 5YU Z C, ZHOU P J, XU D,et al. Investigation on pharmacoki- netics of mycophenolic acid in Chinese adult renal transplant pa- tients[ J]. Br J Clin Pharmacol, 2006, 62 (4) .446-452.
  • 6MICEEL M, JACQUES M, DJAMILA C E, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated withmycophenolate mofetil [J]. Clin Chem,2001;47(1) . 88-94.
  • 7HALE M D, NICHOLLS A J, BULLINGHAM R E, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate ruoatil in renaltransplantation [ J ]. Clin Pharmacol Ther, 1998, 64(6) . 672-6.
  • 8余自成,高瑜,田薇薇,瞿江媛,马明华,陈红君,王艳霞,陈红专.肠道转运Caco-2细胞单层模型的建立及验证评价[J].中国临床药学杂志,2012,21(4):218-221. 被引量:12
  • 9余自成,江涛,瞿江媛,田薇薇,马明华,陈红君,陈红专.用HPLC-MS/MS法同时测定Caco-2细胞单层转运介质中吗替麦考酚酯和麦考酚酸的浓度[J].药学服务与研究,2012,12(6):423-426. 被引量:2
  • 10ZHOU S, FENG X, KESTELL P, et al. Transport of the investi- gational anti-cancer drug 5,6-dimethylxan-thenone-4-acetic acid and its acyl glueuronide by human intestinal Caco-2 cells [ J ]. Ettr J Pharm Sci, 2005, 24(5) .513-524.

二级参考文献35

  • 1焦正,沈杰,张明,仲艳,钟建泳,高志伟,钟明康,郁韵秋.柱后衍生化HPLC测定人血浆中总的和游离麦考酚酸及其葡糖苷酸代谢物[J].中国药学杂志,2005,40(17):1339-1343. 被引量:9
  • 2焦正,沈杰,仲珑瑾,郁韵秋,钟明康.麦考酚酸肠肝循环药动学模型的建立[J].药学学报,2006,41(3):272-276. 被引量:7
  • 3马燕,李沛波,苏薇薇,陈大为.药理实验中Caco-2细胞模型建立的评价指标[J].中药材,2006,29(9):946-948. 被引量:8
  • 4孙敏捷,盛星,胡一桥.Caco-2细胞单层模型的建立与验证[J].中国药学杂志,2006,41(18):1431-1434. 被引量:33
  • 5[1]Pantazis P, Earuj JA, Kozielski AJ, et al. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro [J]. Cancer Res, 1993,53(7) :1577 - 1582.
  • 6[2]Sands H, Mishra A, Stoeckler JD, et al. Preclinical activity of an iv formulation of rubitecan in IDD-PTM against human solid tumor xenografts [ J ]. Anticancer Drugs, 2002,13 (9): 965 - 975.
  • 7[3]Zhong DF, Li K, Xu JH, et al. Pharmacokinetics of 9-nitro-20 (S) -camptothecin in rats [ J ]. Acta Pharmacol Sin, 2003,24 (3) :256 - 262.
  • 8[4]Creemers GJ, Gervits CJH, Eckhardt J. Phase Ⅰ and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors [J].J Clin Oncol, 1997,15(3) :1087 - 1090.
  • 9[5]Chu XY, Suzuki H, Ueda K, et al. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines[J]. J Pharmacol Exp Ther , 1999,288(2) :735 -741.
  • 10[6]Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport[J]. Adv DrugDeliv Rev, 2001,46(1 -3):27 -43.

共引文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部